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Introduction
Type 2 diabetes mellitus (DM) increases an individual’s risk for 
health problems including cardiovascular disease, blindness, 
chronic kidney disease (CKD), and nerve damage1–4. The devel-
opment of kidney disease is associated with other complica-
tions of type 2 diabetes and with poorer outcomes1,3,5. Therefore, 
slowing the development of, or preventing kidney disease is one 
aim of therapy2. Type 2 diabetes drugs are thought to play a 
major role in protecting the kidneys by controlling blood sugar 
levels and may confer additional protective effects according to 
specific drug profiles3. However, as kidney function declines, 
type 2 diabetes drug options become limited due to prescribing 
restrictions2,3,5–7. This presents a challenge for treating type 2 
diabetes in patients with non-diabetic related kidney disease, as 
well as those with renal diabetic complications.
Treatment choice reflects a complex balancing of expected 
risks and benefits. A recent systematic review focused on 
vascular outcomes, glyclated hemoglobin (HbA1c), body weight, 
hypoglycaemia and common adverse events8. Here we focus on 
kidney-related outcomes as another important aspect of clinical 
care that clinicians must consider when prescribing drugs for 
type 2 DM. Our aim was to provide a summary of the current 
evidence of long term kidney outcomes, from comparative, 
long terms studies of oral antidiabetic drugs. We included the 
following outcomes: change in kidney function (estimated 
glomerular filtration rate), progression or development of 
proteinuria, development of end-stage renal disease (ESRD) and 
composite outcomes compared between different oral drugs for 
the treatment of type 2 DM.
Methods
The protocol for this systematic review was submitted, reviewed 
and approved by PROSPERO (International prospective register 
of systematic reviews, ref. 2016: CRD42016036646). The study 
was conducted and is reported in accordance with the PRISMA 
protocol (Supplementary File 1)9.
Data sources and searches
We searched the databases; Medline, Embase and Web of 
Science for articles published between 1st January 1980 and 
15th May 2018. The search comprised keywords and MESH 
terms relating to three broad themes: kidney function, type 2 
diabetes drugs and clinical studies. We limited the search to 
English-language studies, and studies in humans. The search 
strategies are in Supplementary Table 1 and Supplementary 
Table 2 (Supplementary File 2). The reference lists of relevant 
reviews identified through the search were also screened.
Study selection
One reviewer (SW) screened all citations identified in the 
searches. Titles and abstracts for all studies were compared to 
the selection criteria. Then the full-text of selected studies were 
reviewed against the inclusion and exclusion criteria. Reviewer 
two (MI) was blinded to the articles selected by reviewer one and 
screened a 20% sample of the articles selected by reviewer one 
after the title screen. The studies chosen by the two reviewers 
were compared.
We defined the search and screening strategies before complet-
ing the searches. Studies were eligible for inclusion if they were 
clinical studies that (i) compared two or more classes of oral 
therapy for type 2 DM; (ii) reported kidney outcomes as primary 
or secondary outcomes; (iii) included more than 100 participants, 
and (iv) followed participants for 48 weeks or more. We restricted 
the review to oral antidiabetic drugs recommended at the 
initiation and first intensification of treatment6.
We did not include studies that reported only placebo- 
controlled comparisons as we were interested in the difference in 
effects between active therapy regimes to reflect therapy choices 
made in routine clinical care; placebo-controlled studies would 
not estimate this difference. Our definition of a kidney outcome 
was broad to identify as many studies as possible. We accepted 
any kidney-related outcome, including the incidence of chronic 
kidney disease, reduced estimated Glomerular Filtration Rate 
(eGFR), increased creatinine, ‘micro’ and ‘macro’ albuminuria, 
proteinuria, end stage renal disease (ESRD) and compos-
ite kidney outcomes. We did not include composite microv-
ascular outcomes that combined kidney outcomes with other 
microvascular outcomes such as retinopathy or neuropathy.
Data extraction and quality assessment
After study selection, using a predefined data collection tool, we 
extracted data for the following items: number of participants, 
study design, calendar years covered by the study, length of 
follow-up, drug comparison, mean age of study population, 
exclusion criteria for study, kidney measurements taken at 
baseline, mean duration of diabetes, mean HbA1c at baseline, 
primary outcome for the study, kidney outcomes reported and 
results for kidney outcomes reported. Reviewer one (SW) 
assessed each study for quality, using the GRACE 201410 items 
for observational comparative effectiveness research and the 
Cochrane Collaboration tool for assessing risk of bias in 
randomised trials11 for RCTs.
Results
Figure 1 details the study selection process through which we 
found 9,086 potentially eligible studies. The first reviewer (SW) 
completed the initial title screen and selected 1,896 articles. 
The second reviewer (MI) was blinded and reviewed a 20% 
random sample of these articles. The agreement between 
reviewers was good, reviewer two selected an additional paper 
that was rejected after discussion. After subsequent discussions 
(SW, MI and LT), we selected 15 studies.
We identified 15 eligible studies, seven of which were randomised 
controlled trials (RCTs)12–18 and eight were observational 
studies19–26. Across the 15 studies, three RCTs16–18 and one 
observational study22, reported changes in eGFR as an outcome. 
All seven RCTs12–18 and two observational studies22,25 investi-
gated albumin-creatinine ratio (ACR) as an outcome. Six obser-
vational studies reported kidney endpoints, including kidney 
failure, nephropathy, acute dialysis and composite endpoints with 
eGFR19–21,23,24,26. Comparisons made, and outcomes studied are 
summarised graphically in Figure 2. Given the range of the kid-
ney function outcomes reported and the drug class comparisons 
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Figure 1. Flow diagram of study selection. Ovid was used to search the Embase and Medline databases.
made we did not complete a meta-analysis of the results, instead we 
provide a narrative summary of studies. Selected studies and 
their findings are summarised in Table 1 and Table 2.
In total, we identified 32 direct comparisons between oral 
drugs for the treatment of type 2 DM: 22 comparisons between 
monotherapies, three comparisons between dual therapy 
combinations, and seven comparisons between dual therapies and 
monotherapies, outlined in Table 3. One study compared many 
combination therapy options to metformin; we did not 
include the triple therapy combinations from this study in our 
results, details of the comparisons are in Supplementary Table 3 
(Supplementary File 2)23.
Monotherapy comparisons
Metformin monotherapy vs. thiazolidinedione monotherapy. 
The most common drug comparison was metformin monotherapy 
vs. thiazolidinedione monotherapy (five studies made seven 
comparisons)14,16,19,22,23. Two RCTs found that thiazolidinedi-
ones were associated with improved kidney outcomes (reduced 
proteinuria or improved eGFR) compared to metformin14,16 
while two observational studies found no differences between 
the two drug classes19,22. One observational cohort study showed 
that thiazolidinediones were associated with a higher risk for 
development of kidney failure (a composite of kidney dialysis, 
kidney transplant and CKD stage five) compared to metformin23.
Metformin monotherapy vs. sulfonylurea monotherapy. Six 
observational studies19–23,26 compared metformin monotherapy 
to sulfonylurea monotherapy. Though two of these studies 
(19 and 20) reported similar findings from the same source 
population, we have therefore only reported one of the results, 
making six comparisons. Four comparisons favoured metformin. 
One study found the risk of eGFR falling to below 60 mL/min/
1.73m2 was greater in the sulfonylurea group compared to the 
metformin group22. Three found higher risks of kidney failure 
outcomes (various composites of codes for nephropathy, dialysis, 
renal transplant, ESRD, and reductions in eGFR) for sulfonylu-
rea compared to metformin20,21,23. One study, using proteinuria 
as an outcome, found no difference between drug classes22. One 
further study reported higher rates of acute dialysis for people 
initiating metformin compared to sulfonylureas26.
Sulfonylurea monotherapy vs. thiazolidinedione monotherapy. 
Findings from two RCTs showed differences in ACR that were 
not statistically significant12,16. However, one of these studies also 
showed an increase in mean eGFR among patients treated with a 
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Figure 2. Graphical representation of drug comparisons and findings. Connecting lines indicate where studies have made comparisons 
between drugs. Lines connect drug names and are labelled with the authors that made the comparison. Dashed line indicates randomised 
studies, single line indicates non-interventional studies. Findings are indicated by the colour of the line: where one drug appears to be 
protective, the line is the colour of the protective drug. Grey lines indicate no significant difference. E.g. Blue lines connecting metformin to 
sulfonylurea indicate that metformin appeared to be protective of kidney function. Arrow heads point towards the drug that appeared to be 
protective. One further comparison not included here. Hung et al. 2012, as two studies by Hung et al. reported similar comparison using 
similar data* Also includes dipstick and urine protein tests, † metformin group largely metformin, but some taking TZD or SU. Abbreviations: 
MTF: metformin, SU: sulfonylurea, TZD: Thiazolidinedione, DPP4i: Dipeptidyl peptidase-4 inhibitor, ACA: acarbose, SGLT: Sodium-glucose 
Cotransporter 2 inhibitors, GLP1: Glucagon-like peptide-1 receptor agonist, eGFR: estimated Glomerular Filtration Rate, ACR: Albumin 
creatinine ratio, ARF: Acute renal failure.
Sulfonylurea monotherapy vs. SGLT2i monotherapy. One 
RCT showed canagliflozin slowed kidney function decline, and 
reduced albuminuria, compared to glimepiride17.
Combination therapy comparisons
Only three studies compared combination therapies.
Metformin plus sulfonylurea vs. metformin plus thiazolidinedi-
one. One RCT compared metformin plus sulfonylurea to metformin 
plus a thiazolidinedione15. They reported that ACR decreased in 
the metformin plus thiazolidinedione group and increased in the 
metformin plus sulfonylurea group15.
Sulfonylurea plus metformin vs. sulfonylurea plus thiazolid-
inedione. One RCT compared sulfonylurea plus metformin to 
sulfonylurea plus thiazolidinedione13. The study found that the 
ACR increased in the sulfonylurea plus metformin group, and 
decreased in the sulfonylurea plus thiazolidinedione group13.
Metformin plus sulfonylurea vs. metformin plus gliptin (DPP4i). 
One observational study compared metformin plus sulfonylu-
rea combination therapy to metformin plus sitagliptin25. The 
results showed weak evidence that metformin plus sitagliptin 
improved the likelihood of reductions in ACR, with an odds ratio 
of 1.20 (95% CI: 0.99–1.47, P = 0.063)25.
Dual therapy vs. monotherapy
Three observational studies made seven comparisons between 
monotherapy options and combination therapy20,21,23. One 
study indicated that people taking metformin were at a lower 
risk of renal failure compared to people taking metformin plus 
sulfonylurea21. Another study found the opposite, people taking 
metformin plus sulfonylurea were at lower risk of kidney failure 
compared to metformin23. The same study found no differences 
in the risk of kidney failure compared to metformin in people 
prescribed; i) metformin plus thiazolidinedione, and ii) metformin 
plus gliptin. They also reported that people prescribed sulfo-
nylurea plus thiazolidinedione, and a sulfonylurea plus DPP4i 
were at higher risk for kidney failure compared to metformin23.
Another observational study found no difference in eGFR 
outcomes between sulfonylurea monotherapy and metformin plus 
sulfonylurea combination therapy20.
Study quality
We assessed each study for quality, using the GRACE 201410 
items for observational comparative effectiveness research 
and the Cochrane Collaboration risk of bias tool for RCTs11 
Supplementary Table 5 and Supplementary Table 6 (Supplemen-
tary File 2) detail the results. For the RCTs, we assessed study 
quality as good, though few studies reported details of randomi-
sation techniques. Of the observational studies, reporting was 
reasonable, according to the GRACE criteria. However, many 
of the studies made comparisons between drugs used at differ-
ent stages of drug intensification, or between monotherapy and 
combination therapy. For example, two observational studies21,23 
used metformin monotherapy as the baseline in comparisons 
with combination therapy. As metformin monotherapy is the 
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Table 3. Results summary.
RCTs Observational
Number Results Number Results
ACR
Monotherapy
MTF     vs     ACA 1 Favours ACA 0
MTF     vs     SU 0 1 No difference
MTF     vs     TZD 2 Both favour TZD 1 No difference
SU     vs    SGLT 1 Favours SGLT 0
SU     vs    TZD 2 Both no difference 0
Dual therapy
MTF+SU    vs     MTF+DPP4i 0 1 No difference
MTF+TZD     vs     MTF+SU 1 Favours MTF+TZD 0
SU+TZD     vs     SU+MTF 1 Favours SU+TZD 0
eGFR
Monotherapy
MTF     vs     ACA 1 No difference 0
MTF     vs     SU 0 1 Favours MTF
MTF     vs     TZD 1 Favours TZD 1 No difference
SU     vs     SGLT 1 Favours SGLT 0




MTF     vs     DPP4i 0 1 Favours MTF
MTF     vs     SU 0 4 3 favour MTF, 1 favours SU
MTF     vs     TZD 0 2 1 no difference, 1 favours MTF
SU     vs     DPP4i 0 1 No difference
Mono vs. dual therapy
MTF     vs     MTF+DPP4i 0 1 No difference
MTF     vs     MTF+SU 0 2 1 favours MTF, 1 favours MTF+SU
MTF     vs      MTF+TZD 0 1 No difference
MTF     vs     SU+DPP4i 0 1 Favours MTF
MTF     vs     SU+TZD 0 1 Favours MTF
SU     vs     MTF+SU 0 1 No difference
Abbreviations: ACR: Albumin: Creatinine Ratio, eGFR: estimated glomerular filtration rate, MTF: metformin, SU: sulfonylurea, TZD: 
Thiazolidinedione, DPP4i: Dipeptidyl peptidase-4 inhibitor, ACA: acarbose, , EXE: Exenatide. SGLT: SGLT2i, GLP1: Glucagon-like 
peptide-1 receptor anonist, IPW: Inverse Probability Weight, FU: Follow-up, SD: Standard deviation, ARF: Acute Renal Failure, CKD: 
Chronic Kidney Disease, IQR: Inter Quartile Range, p-yr: person-years, NR: Not reported, DB: Database, KDIGO: Kidney Disease: 
Improving Global Outcomes. One further comparison not included here. Hung et al. 2012, as two studies by Hung et al. reported 
similar comparison using similar data
most common drug for initiating treatment, and the addition 
of other drugs to metformin is likely to be associated with pro-
gression or poor control of type 2 DM, comparing metformin to 
drug prescribed at the first stage of intensification is problematic, 
particularly for renal outcomes. Those people receiving treatment 
intensification will tend to be sicker, and distinguishing between the 
effects of treatment and the effects of the underlying disease may 
not always be possible.
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Conclusion
Key findings
Overall, we have found a lack of consistent evidence of long-
term differences in kidney outcomes between T2DM drugs. In 
comparisons of treatments for type 2 DM, for thiazolidinediones 
vs metformin, there is some evidence of reduced proteinuria - of 
four comparisons with ACR as an outcome (in combination or 
monotherapy), three favoured TZD and one showed no differ-
ence. Most evidence from observational research also suggested 
that metformin is associated with better kidney outcomes than 
sulfonylureas.
Despite frequent use of combination therapies for the treatment 
of diabetes, we found few studies that compared commonly used 
dual therapies that investigated renal outcomes.
Previous work
The finding that thiazolidinediones may reduce proteinuria 
compared with metformin is aligned with observations of other 
authors and supported by animal studies27,28. Though previous 
evidence is limited, other work suggests that TZDs could exert 
reno-protective effects via a number of pathways, including 
reducing blood pressure28. TZDs may also act directly in the 
kidneys via proliferator-activated receptor gamma (PPARg), 
found in the kidney (and in other tissue)27,28. However, changes 
in estimated GFR may reflect changes in fluid status rather than 
true changes in renal function, which was not measured directly in 
any study29.
Strengths
To our knowledge, this is the first systematic review of the 
comparative research literature that investigated the effects of 
type 2 diabetes drug regimens on renal function. We have 
conducted an extensive and detailed search, with broad defini-
tions of renal function.
Limitations
We have focused on renal outcomes only but recognize this is 
just one of many safety and effectiveness factors to be considered 
when deciding treatment options. Despite the importance of care-
ful monitoring and maintenance of kidney function for people with 
diabetes, we identified just 15 long-term studies reporting 
renal outcomes. Renal complications of type 2 diabetes take 
many years to develop after the onset of diabetes and studies may 
not be adequately powered or have sufficient length of follow-
up to detect differences. Therefore, many studies have used the 
surrogate marker of changes in proteinuria as a marker of 
clinical renal outcomes. Further, initial changes in kidney 
function may be misleading. One included study indicates benefits 
of canagliflozin over glimipiride for kidney function decline 
at 104 weeks: however these benefits were not apparent until 
52 weeks17,30. This and the EMPA-REG study31 have indicated 
initial acute falls in eGFR with better outcomes compared to 
placebo only observed over the longer term so this would not be 
apparent in short-term studies.
Our review included both randomised and non-interventional 
studies. Whilst the unique inferential advantages of randomization 
are clear, our review highlights a large overall difference in 
population size depending on study type: randomised trials 
generally included hundreds of patients, whilst non-interven-
tional studies often had tens of thousands of participants. Rarer 
outcomes such as ESRD are therefore more likely to be detected 
in non-interventional settings. This highlights their important 
role, but the evidence generated from them needs to be evaluated 
cautiously due to the potential for bias and confounding.
The available evidence does not reflect drugs currently prescribed 
in routine care. In our review, 69% (22/32) of the comparisons, 
contrasted different monotherapies, with just three comparisons 
between dual therapy combinations. In clinical practice, 
metformin is the most common first-line therapy, and GPs now 
rarely prescribe thiazolidinediones (EU marketing authorization 
for Rosiglitazone was suspended in 201032, following concern 
regarding increased heart failure risk)33.
In the UK, NICE guidance recommends the addition of 
sulfonylureas, Dipeptidyl peptidase-4 inhibitors (DPP4is) 
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2is), or TZDs 
to metformin, yet, just one study compared these combinations 
(MTF+SU vs MTF+DPP4i)25,33–35. Recent studies that have 
shown potentially exciting improvements in renal outcomes for 
patients treated with SGLT2is were conducted against placebo 
and so were not eligible for this study36,37.
We found that definitions of kidney outcomes were not consistent 
across studies. Definitions of renal decline in the observa-
tional studies relied upon either codes for kidney disease 
(e.g. diabetic nephropathy, acute renal failure), surrogate markers 
(e.g. eGFR or proteinuria) or a combination of codes and tests, sum-
marised in Supplementary Table 4 (Supplementary File 2). For the 
albuminuria data, which has a skewed distribution, most studies 
used logarithmic transformation to approximate normal, yet 
not all studies applied this method18. Such differences between 
outcomes will limit future opportunities for pooling effect 
estimates in meta-analyses. Different approaches to study design 
may also limit the validity of findings. We found two observa-
tional studies that made the same comparisons yet found different 
effects. Both examined renal failure, using UK primary care data, 
(QResearch23 and Clinical Practice Research Datalink21). They 
found comparable effect sizes when comparing the use of 
sulfonylurea monotherapy to metformin monotherapy, for renal 
failure (2.63, 95% CI: 2.25, 3.0623 and 2.63, 95% CI: 2.19, 
3.1521). However, when comparing sulfonylurea plus metformin 
dual therapy to metformin monotherapy, estimates of the risk of 
kidney failure were in opposite directions (0.76, 95% CI: 0.62, 
0.9223 and 1.39, 95% CI: 1.12, 1.7221). Difficulties in adjusting for 
levels of diabetic control or change in renal function that led to 
these treatment choices (confounding by indication), may explain 
these conflicting results.
In the randomised controlled studies, we found that eligibility 
criteria were strict. Many studies excluded people most at risk of 
kidney outcomes e.g. those with reduced kidney function or 
cardiovascular disease12,13,15–18. These restrictions limit the gen-
eralisability of study findings to routine clinical settings where 
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people presenting with diabetes have complex comorbidities38. 
Further, as most individuals with type 2 diabetes will receive 
treatment for other comorbid conditions, prescribers need to 
know how diabetic therapies interact with concomitant drugs, yet 
this is not addressed by the studies identified in this review.
Clinical relevance
In clinical practice, kidney function is one of many considera-
tions for treatment choice in type 2 DM. Some of the differences 
we found for albuminuria and eGFR between people taking 
different oral therapies for type 2 diabetes were statistically 
significant, but the clinical importance of these findings may be 
limited. Some surrogate outcomes such as a doubling of cre-
atinine or 30% decline in eGFR are closely associated with 
risk of future ESRD39,40 while ACR is not39,41,42. Outcomes that 
are clinically relevant need to be assessed in future studies. 
Ideally, these should include hard outcomes such as hospital 
admission with acute kidney injury or the development of ESRD. 
Therefore, large, well-designed studies with long follow up, 
including individuals that represent the typical type 2 diabetes 
population, will be required. However, the incidence of kidney 
outcomes is likely to be low in most randomised trials and 
therefore high-quality observational studies will also be needed.
Our review highlights a lack of rigorous studies comparing 
the effects of oral type 2 diabetes drugs on kidney outcomes, in 
particular, for the newer drug intensification options where 
prescribing is rapidly increasing.
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The introduction states that the study focuses on “following outcomes: change in kidney function
(estimated glomerular filtration rate), progression or development of proteinuria, development of
 (page 3). However in the result sectionend-stage renal disease (ESRD) and composite outcomes”
following outcomes are mentioned “changes in eGFR […] albumin-creatinine ratio (ACR) […]
kidney endpoints, including kidney failure, nephropathy, acute dialysis and composite endpoints
(page 3)  Finally, in Table 3 the studies are divided in the three groups “with eGFR” . ACR, eGFR,
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